GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) » Definitions » Net Cash per Share

Dr. Lal PathLabs (NSE:LALPATHLAB) Net Cash per Share : ₹80.57 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Dr. Lal PathLabs Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Dr. Lal PathLabs's Net Cash per Share for the quarter that ended in Mar. 2025 was ₹80.57.

The historical rank and industry rank for Dr. Lal PathLabs's Net Cash per Share or its related term are showing as below:

NSE:LALPATHLAB' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 16.46   Med: 32.79   Max: 159.52
Current: 35.37

During the past 13 years, the highest Price-to-Net-Cash Ratio of Dr. Lal PathLabs was 159.52. The lowest was 16.46. And the median was 32.79.

NSE:LALPATHLAB's Price-to-Net-Cash is ranked worse than
88.57% of 70 companies
in the Medical Diagnostics & Research industry
Industry Median: 5.72 vs NSE:LALPATHLAB: 35.37

Dr. Lal PathLabs Net Cash per Share Historical Data

The historical data trend for Dr. Lal PathLabs's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr. Lal PathLabs Net Cash per Share Chart

Dr. Lal PathLabs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68.12 -19.75 11.46 40.37 80.57

Dr. Lal PathLabs Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.37 - 67.81 - 80.57

Competitive Comparison of Dr. Lal PathLabs's Net Cash per Share

For the Diagnostics & Research subindustry, Dr. Lal PathLabs's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dr. Lal PathLabs's Price-to-Net-Cash Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Dr. Lal PathLabs's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Dr. Lal PathLabs's Price-to-Net-Cash falls into.


;
;

Dr. Lal PathLabs Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Dr. Lal PathLabs's Net Cash per Share for the fiscal year that ended in Mar. 2025 is calculated as

Net Cash per Share (A: Mar. 2025 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(12158-5103-338)/83.367
=80.57

Dr. Lal PathLabs's Net Cash per Share for the quarter that ended in Mar. 2025 is calculated as

Net Cash per Share (Q: Mar. 2025 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(12158-5103-338)/83.367
=80.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dr. Lal PathLabs  (NSE:LALPATHLAB) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Dr. Lal PathLabs Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Dr. Lal PathLabs's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Dr. Lal PathLabs Business Description

Traded in Other Exchanges
Address
12th Floor, Tower B, SAS Tower, Sector 38, Medicity, Gurugram, HR, IND, 122 001
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the area of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist to prevent, monitor and treat diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.

Dr. Lal PathLabs Headlines

No Headlines